Sulzer Medica confident with new $1 billion implants plan
This article was originally published in Clinica
Sulzer Medica may be a mere few months away from settling the faulty Inter-Op hip implant saga that dogged it for all of last year and caused its share price to crumple to a fraction of its value before the event. The Swiss company has formed a new $1 billion proposed settlement after negotiations that included the plaintiffs' lawyers. Shares in the company leapt by over 20% to around SFr110 ($65) on the disclosure.
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.